However, TET2 mutations were also reported to have no impact on the clinical outcomes of de novo AML [48, 49], CN-AML [49, 50], and CN-AML with mutated NPM1 or CEBPA without FLT3ITD [41]. The gene discussed is NPM1; the disease is acute myeloid leukemia.